[Oncolytic parvoviruses. A new approaches for cancer therapy].
Parvoviruses such as parvovirus H-1 (H-1PV) may selectively infect and lysis cancer cells. The parvoviruses also induce an immune system to eliminate the tumor cells through the formation of anti-cancer immunity. One of the possible mechanisms of antitumor activity is associated with the direct induction of apoptosis by parvoviral proteins NS1 and 11 kDa. Parvovirus-based vectors are promising for gene therapy of oncological diseases and genetic disorders in humans. Parvoviruses were successfully used for the experimental treatment on animal models of human glioma, neuroblastomas, lymphomas, pancreatic carcinoma, carcinomas and breast tumors. ParvOryx is the first oncolytic preparation constructed on the base of H-1PV; its phase I/IIa clinical trials in patients with glioblastoma multiforme are in process.
V B
VB
Loktev
T Iu
TIu
Ivan'kina
S V
SV
Netesov
P M
PM
Chumakov
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D005260:Female; D005822:Genetic Vectors; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy; D052661:H-1 parvovirus / Q000737:chemistry; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses; D017361:Viral Nonstructural Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; C106202:NS1 protein, parvovirus; D017361:Viral Nonstructural Proteins